{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:16:29Z","timestamp":1786115789472,"version":"build-2736575974"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ebm-journal.org"],"crossmark-restriction":true},"short-container-title":["Exp. Biol. Med."],"abstract":"<jats:p>Oncolytic viruses (OVs) are a class of viruses capable of specifically infecting and killing tumor cells. They exert antitumor effects through direct lysis of tumor cells, activation of the immune system, and disruption of tumor vasculature. Neutrophils, which originate from the bone marrow, are the most abundant leukocytes in peripheral blood and the immune system and play a dual regulatory role in oncolytic virotherapy. In different TME, neutrophils can polarize into two phenotypes: N1 and N2. N1 neutrophils, owing to their chemotaxis and tumor-homing capabilities, can serve as delivery vehicles for OVs, enhance the therapeutic efficacy of oncolytic virotherapy, and activate host immune responses. In contrast, N2 neutrophils impair the efficacy of OVs through their antiviral activity and immunosuppressive functions. Therefore, an in-depth understanding of the mechanisms underlying the role of neutrophils in oncolytic virotherapy is of great significance for optimizing OV-based therapies and improving their clinical application outcomes.<\/jats:p>","DOI":"10.3389\/ebm.2026.11192","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:10:17Z","timestamp":1785993017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The role and mechanism of neutrophils in oncolytic virus therapy"],"prefix":"10.3389","volume":"251","author":[{"given":"Baixian","family":"Huang","sequence":"first","affiliation":[{"name":"School of Medicine, Foshan University","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixin","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medicine, Foshan University","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Foshan University","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochao","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Medicine, Foshan University","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"795300","DOI":"10.3389\/fbioe.2021.795300","article-title":"Electrical stimulation for immune modulation in cancer treatments","volume":"9","author":"Das","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12094-012-0951-7","article-title":"Viruses in cancer treatment","volume":"15","author":"Alemany","year":"2013","journal-title":"Clin & Translational Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-981-10-7230-7_4","article-title":"Oncolytic virotherapy by HSV","volume":"1045","author":"Watanabe","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trsl.2021.04.008","article-title":"Development of oncolytic viruses for cancer therapy","volume":"237","author":"Abd-Aziz","year":"2021","journal-title":"Transl Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/ijms25021180","article-title":"Oncolytic virotherapy: a new paradigm in cancer immunotherapy","volume":"25","author":"Volovat","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus-T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/1566523218666180910163805","article-title":"Oncolytic virotherapy for breast cancer treatment","volume":"18","author":"Sm","year":"2018","journal-title":"Curr Gene Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1188526","DOI":"10.3389\/fmicb.2023.1188526","article-title":"Development and application of oncolytic viruses as the nemesis of tumor cells","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.immuni.2010.11.011","article-title":"Neutrophils, from marrow to microbes","volume":"33","author":"Borregaard","year":"2010","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7326\/0003-4819-109-2-127","article-title":"Neutrophils and host defense","volume":"109","author":"Lehrer","year":"1988","journal-title":"Ann Intern Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.omto.2020.12.011","article-title":"CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy","volume":"20","author":"Pan","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"115226","DOI":"10.1016\/j.celrep.2024.115226","article-title":"NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression","volume":"44","author":"Xu","year":"2025","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10555-018-9759-4","article-title":"Cross-talk between lung cancer and bones results in neutrophils that promote tumor progression","volume":"37","author":"Azevedo","year":"2018","journal-title":"Cancer Metastasis Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s13058-025-02201-8","article-title":"Neutrophils matter: new clinical insights on their role in the progression of metastatic breast cancer","volume":"27","author":"Correia","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.devcel.2024.10.010","article-title":"A subset of neutrophils activates anti-tumor immunity and inhibits non-small-cell lung cancer progression","volume":"60","author":"Tang","year":"2025","journal-title":"Dev Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41590-025-02126-6","article-title":"Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder cancer","volume":"26","author":"Zhu","year":"2025","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"A528","DOI":"10.1136\/jitc-2025-SITC2025.0463","article-title":"463 dissecting myeloid-driven mechanisms of immunotherapy resistance in prostate cancer bone metastases","volume":"13","author":"Lyu","year":"2025","journal-title":"J ImmunoTherapy Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u0394: first approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"114756","DOI":"10.1016\/j.celrep.2024.114756","article-title":"HSV-1-induced N6-methyladenosine reprogramming via ICP0-mediated suppression of METTL14 potentiates oncolytic activity in glioma","volume":"43","author":"Chen","year":"2024","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/21645515.2020.1799667","article-title":"Extracellular vesicles of bacteria as potential targets for immune interventions","volume":"17","author":"Peng","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B25","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1177\/00031348211023434","article-title":"Surgical resection after talimogene laherparepvec for melanoma: persistent fuorodeoxyglucose avidity on positron emission tomography despite no viable disease","volume":"87","author":"MacArthur","year":"2021","journal-title":"Am Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41467-024-48032-7","article-title":"Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1073\/pnas.95.7.3954","article-title":"Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice","volume":"95","author":"Miyahira","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.14202\/vetworld.2024.2688-2693","article-title":"The oncolytic effect of Newcastle disease virus attenuated AMHA1 strain against digestive system tumors","volume":"17","author":"Hamad","year":"2024","journal-title":"Vet World"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.7150\/thno.83495","article-title":"OX40L-Armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment","volume":"13","author":"Liu","year":"2023","journal-title":"Theranostics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2404965","DOI":"10.1002\/adhm.202404965","article-title":"Oncolytic virus targeted therapy for glioma via intravenous delivery","volume":"14","author":"He","year":"2025","journal-title":"Adv Healthc Mater"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/cells13211815","article-title":"VEGF-virus interactions: pathogenic mechanisms and therapeutic applications","volume":"13","author":"S\u00e1nchez-Mart\u00ednez","year":"2024","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"102314","DOI":"10.1016\/j.xcrm.2025.102314","article-title":"In vivo neutrophils hitchhiking for tumor targeting and microenvironment regulation boosts oncolytic virus therapy","volume":"6","author":"Zhao","year":"2025","journal-title":"Cell Rep Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1002\/cam4.2332","article-title":"Engineering macrophages to phagocytose cancer cells by blocking the CD47\/SIRP\u0251 axis","volume":"8","author":"Yang","year":"2019","journal-title":"Cancer Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4014\/jmb.1509.09051","article-title":"Structural and functional insight into proliferating cell nuclear antigen","volume":"26","author":"Park","year":"2016","journal-title":"J Microbiol Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/v16081264","article-title":"Proliferating cell nuclear antigen in the era of oncolytic virotherapy","volume":"16","author":"Kwan","year":"2024","journal-title":"Viruses"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.3390\/cells11182858","article-title":"The role of neutrophils in oncolytic orf virus-mediated cancer immunotherapy","volume":"11","author":"Minott","year":"2022","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/vaccines12091010","article-title":"Dose considerations for vaccinia Oncolytic virus based on retrospective reanalysis of early and late clinical trials","volume":"12","author":"Cyrelle Ornella","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6347","DOI":"10.3390\/ijms21176347","article-title":"Characterization of the impact of oncolytic vesicular stomatitis virus on the trafficking, phenotype, and antigen presentation potential of neutrophils and their ability to acquire a non-structural viral protein","volume":"21","author":"Stegelmeier","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12985-022-01757-7","article-title":"Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model","volume":"19","author":"Tang","year":"2022","journal-title":"Virol J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-003000corr1","article-title":"Correction: novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids","volume":"9","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/mt.2015.149","article-title":"The role of neutrophils in measles virus-mediated oncolysis differs between B-cell malignancies and is not always enhanced by GCSF","volume":"24","author":"Dey","year":"2016","journal-title":"Mol Ther"},{"key":"B44","first-page":"6463","article-title":"Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression","volume":"63","author":"Grote","year":"2003","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.omtm.2022.07.014","article-title":"Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. Pylori immunostimulatory bacterial transgene","volume":"26","author":"Viker","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41417-025-00875-y","article-title":"Biodistribution and toxicity evaluation of oncolytic adenovirus Adf35(OGN) in Syrian hamster and mouse","volume":"32","author":"Yngve","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1038\/s41467-024-49059-6","article-title":"Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy","volume":"15","author":"Tang","year":"2024","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1016\/j.cell.2021.04.016","article-title":"Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1073\/pnas.1003893107","article-title":"A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/ibd\/izac225","article-title":"Hypoxic ASCs-derived exosomes attenuate colitis by regulating macrophage polarization via miR-216a-5p\/HMGB1 axis","volume":"29","author":"Qian","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-025-03358-y","article-title":"Viral expression of NE\/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory\/effector CD8(+) T cell infiltration","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ccell.2016.06.001","article-title":"Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer","volume":"30","author":"Singhal","year":"2016","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"10840","DOI":"10.1128\/jvi.01524-14","article-title":"Chemokine (C-C motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara","volume":"88","author":"Price","year":"2014","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/mt.2011.132","article-title":"A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma","volume":"19","author":"Hwang","year":"2011","journal-title":"Mol Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.immuni.2021.06.006","article-title":"The neutrophil","volume":"54","author":"Burn","year":"2021","journal-title":"Immunity"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1038\/s41590-024-02006-5","article-title":"The diverse roles of neutrophils from protection to pathogenesis","volume":"25","author":"Herro","year":"2024","journal-title":"Nat Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/cas.16105","article-title":"Transient inhibition of neutrophil functions enhances the antitumor effect of intravenously delivered oncolytic vaccinia virus","volume":"115","author":"Zhou","year":"2024","journal-title":"Cancer Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/s42003-022-04254-3","article-title":"Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes","volume":"5","author":"Naumenko","year":"2022","journal-title":"Commun Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1134\/s0006297914120025","article-title":"Neutrophil extracellular traps: mechanisms of formation and role in health and disease","volume":"79","author":"Vorobjeva","year":"2014","journal-title":"Biochemistry (Mosc)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.virusres.2016.11.033","article-title":"Understanding the molecular mechanisms of NETs and their role in antiviral innate immunity","volume":"228","author":"Agraz-Cibrian","year":"2017","journal-title":"Virus Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41467-023-44576-2","article-title":"Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma","volume":"15","author":"Dai","year":"2024","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ijc.28770","article-title":"Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity","volume":"135","author":"Mishalian","year":"2014","journal-title":"Int J Cancer"},{"key":"B64","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","article-title":"Defining myeloid-derived suppressor cells","volume":"24","author":"Akkari","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e148960","DOI":"10.1172\/jci.insight.148960","article-title":"Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment","volume":"7","author":"Oo","year":"2022","journal-title":"JCI Insight"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e70044","DOI":"10.1002\/cnr2.70044","article-title":"The recruitment and immune suppression mechanisms of myeloid-derived suppressor cells and their impact on bone metastatic cancer","volume":"8","author":"Li","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","article-title":"CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial","volume":"42","author":"Armstrong","year":"2024","journal-title":"Invest New Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/0008-5472.Can-21-4045","article-title":"A novel selective inhibitor JBI-589 targets PAD4-Mediated neutrophil migration to suppress tumor progression","volume":"82","author":"Deng","year":"2022","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"218153","DOI":"10.1016\/j.canlet.2025.218153","article-title":"SB225002 enhances radiosensitivity in cervical cancer via direct neutrophil inhibition and tumor cell suppression","volume":"638","author":"Ni","year":"2026","journal-title":"Cancer Lett"}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2026.11192\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:10:18Z","timestamp":1785993018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2026.11192\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":69,"alternative-id":["10.3389\/ebm.2026.11192"],"URL":"https:\/\/doi.org\/10.3389\/ebm.2026.11192","relation":{},"ISSN":["1535-3699"],"issn-type":[{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"11192"}}